The Indian pharmaceutical market is one of the fastest growing in the world. Tunes Pharma is positioned in the chronic therapy segment — an area of consistent, compounding demand driven by rising prevalence of lifestyle diseases.
India's pharmaceutical market is projected to grow at 12% CAGR — driven primarily by chronic disease management and branded generics adoption.
The overall Indian pharmaceutical industry — encompassing generics, branded generics, OTC, and speciality drugs across all therapy areas and channels.
Branded generic prescription drugs in chronic therapy areas (Cardiology, Diabetology, Neurology, Gastro, Derma) across Tier 1 and Tier 2 markets in South India.
Our near-term reachable segment — branded generic chronic therapy prescriptions in Andhra Pradesh and Telangana through our field and distribution network.
The chronic therapy segment is driven by seven key areas. Tunes Pharma operates primarily in Diabetology, Cardiology, Gastro, and General Medicine — four of the largest segments.
Chronic diseases require long-term prescription adherence — creating predictable, recurring demand and building loyal prescriber relationships over time.
India has over 77 million diabetics and 220 million hypertensives. The demand for diabetes, cardiology, and nephrology medicines is growing rapidly — and will continue to for decades.
In the Indian market, doctors prefer branded generics over unbranded ones for chronic conditions. Our portfolio is designed to compete on quality and clinical credibility, not just price.
Markets like Guntur, Vijayawada, and surrounding districts have growing specialist counts but limited quality branded generic representation — our primary growth opportunity.
We are a lean, relationship-driven pharmaceutical marketing company. Our model is built for profitability without external funding — growing organically through repeat prescriptions and distributor trust.
Cardiology, Diabetology, Nephrology, and General Medicine — all chronic, all high-repeat, all specialist-driven.
Our team's 20+ years of experience across IPCA, SUN, NOVARTIS, ALKEM, LUPIN, USV, and UNICHEM brings immediate credibility with prescribers and distributors.
We are building from our home base in Guntur and expanding district by district — proving the model before scaling to other states.
As an early-stage startup with zero investor funding, Tunes Pharma has already demonstrated real commercial traction in its launch markets across Andhra Pradesh — proving the model works organically.
Every rupee of revenue has been earned through prescription-driven sales — validating our go-to-market model before seeking external capital for scale.
Unlike large multispecialty players, Tunes Pharma is purpose-built for chronic therapy in Tier 2 and Tier 3 markets — combining the agility of a startup with the credibility of a 20+ year industry veteran.
| Dimension | Tunes Pharma | Sun Pharma | Lupin |
|---|---|---|---|
| Focus | Chronic specialty | Large multispecialty | Large multispecialty |
| Mission | Affordability & community | Growth & profitability | Growth & profitability |
| Production | Strategic partnerships | In-house manufacturing | In-house manufacturing |
| Strengths | Agility, cost-effectiveness, community focus | Scale, diverse portfolio | R&D, acquisitions |
